Dr Hiltermann on ARTEMIDE-01 Data With Rilvegostomig in Metastatic NSCLC

T. Jeroen N. Hiltermann, MD, faculty of medical sciences, University of Groningen, discusses findings from phase 1/2 ARTEMIDE-01 trial (NCT04995523), which is the first-in-human study of the anti–PD-1/TIGIT bispecific antibody rilvegostomig for the treatment of patients with metastatic non–small cell lung cancer with a PD-L1 tumor proportion score of at least 1% who have not received a prior checkpoint inhibitor.